Company
Headquarters: Vienne, France
Employees: 195
€112.0 Million
EUR as of July 1, 2024
US$120.3 Million
Company | Market Cap (USD) |
---|---|
Lilly | $808.65 B |
Johnson & Johnson | $350.63 B |
Merck | $318.75 B |
AbbVie | $295.34 B |
AstraZeneca | $236.45 B |
Company | Market Cap (USD) |
---|---|
Lilly | $808.65 B |
Novo Nordisk | $622.07 B |
UnitedHealth Group | $450.89 B |
Johnson & Johnson | $350.63 B |
Merck | $318.75 B |
Eurofins Cerep SA provides various drug discovery services to pharmaceutical and biotechnology companies worldwide. The company's research services include compound management, high-throughput screening, in vitro safety profiling, lead optimization (or SAR) profiling, in vitro ADME profiling, and in vivo PK. It also offers assay design and development services. The company was formerly known as Cerep SA and changed its name to Eurofins Cerep SA in June 2014. Eurofins Cerep SA was founded in 1989 and is based in Vienne, France.
Top 1-year algo backtest: +265.99%
$10,000 in October 2023 would now be $36,599 by following this algorithm daily at market close.
Use AI to boost your investing & swing trading, now!
Try Disfold DeepFinance FREE
Eurofins-Cerep has the following listings and related stock indices.
Stock: Euronext: ALECR wb_incandescent